Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand
September 4, 2024
Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.
- Buyers
- Bend Bioscience
- Targets
- CoreRx, Societal CDMO
- Industry
- Pharmaceuticals
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
CoreRx, Inc. Acquires Societal CDMO, Inc.
April 8, 2024
Pharmaceuticals
CoreRx, Inc. completed its acquisition of Societal CDMO, Inc. through a tender offer and subsequent short-form merger, acquiring approximately 92.8% of outstanding shares at $1.10 per share. Societal CDMO is now a wholly owned subsidiary of CoreRx and its common stock will be delisted from the Nasdaq Capital Market.
-
CoreRx Acquires Nucleo Life Sciences
May 24, 2021
Pharmaceuticals
CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.
-
NovaQuest Private Equity Acquires CoreRx, Inc.
January 19, 2021
Pharmaceuticals
NovaQuest Private Equity acquired CoreRx, Inc., a Clearwater, Florida–based contract development and manufacturing organization (CDMO). Affiliates of Signet Healthcare Partners will retain a minority stake; Goldman Sachs Specialty Lending Group provided debt financing. NovaQuest said the investment will support continued growth and capability expansion of CoreRx's clinical and commercial CDMO services.
-
BioCina and NovaCina Merge to Create Integrated Global CDMO
January 13, 2025
Pharmaceuticals
BioCina and NovaCina announced a strategic merger that will combine BioCina's process development and manufacturing capabilities in Adelaide with NovaCina's sterile fill-finish facility in Perth. The combined company will retain the BioCina name and provide an end-to-end CDMO offering for small molecules and biopharmaceuticals, backed by parent Bridgewest Group.
-
Nitto Denko Acquires Bend Labs, Inc.
June 1, 2022
Medical Devices
Nitto Denko Corporation has acquired Bend Labs, Inc., a Farmington, Utah-based developer of flexible sensor technologies. Bend will merge into the Nitto Group as Nitto Bend Technologies to combine Bend's sensor devices with Nitto's adhesive and flexible printed circuit capabilities to develop next-generation products and sensor-data services for automotive, healthcare, sports and robotics markets.
-
Asahi Kasei Medical Acquires Bionova Scientific
April 14, 2022
Biotechnology
Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.